Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aptose Biosciences. Inc. (NASDAQ: APTO).

Full DD Report for APTO

You must become a subscriber to view this report.


Recent News from (NASDAQ: APTO)

OHSU and Aptose Present New CG-806 Preclinical Data at ASH 60th Annual Meeting
PORTLAND, Ore. and SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Oregon Health & Science University (OHSU) and Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today announced the presentation of preclinical data demonstrating that CG-806, a first-in-class pan-FLT3/pan-BTK inhibitor, exh...
Source: GlobeNewswire
Date: December, 03 2018 07:10
Aptose Presents New Preclinical Data on CG-806 PAN-FLT3/PAN-BTK Inhibitor at ASH 60th Annual Meeting
SAN DIEGO and TORONTO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today announced the presentation of preclinical data from research led by The University of Texas MD Anderson Cancer Center exploring the mechanism by which CG-806, a highly potent pan-...
Source: GlobeNewswire
Date: December, 03 2018 07:05
Aptose to Participate in Upcoming Investor Conferences, Host Key Opinion Leader Event, and Present Data at the Upcoming ASH Meeting
SAN DIEGO and TORONTO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today an...
Source: GlobeNewswire
Date: November, 20 2018 07:05
Aptose Biosciences Inc. (APTO) CEO William Rice on Q3 2018 Results - Earnings Call Transcript
Aptose Biosciences Inc (APTO) Q3 2018 Earnings Conference Call November 07, 2018, 08:00 PM ET Executives Susan Pietropaolo - SMP Communications William Rice - Chairman, President, and CEO Gregory Chow - SVP and CFO Analysts Jotin Marango - ROTH Capital Joe Pantginis - HC ...
Source: SeekingAlpha
Date: November, 07 2018 14:44
Aptose Biosciences reports Q3 results
Aptose Biosciences (NASDAQ: APTO ): Q3 GAAP EPS of -$0.16. More news on: Aptose Biosciences Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 06 2018 17:32
Aptose Reports Results for the Third Quarter Ended September 30, 2018
Conference call is scheduled for tomorrow, Wednesday, November 7 th at 8:00 AM ET SAN DIEGO and TORONTO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing high...
Source: GlobeNewswire
Date: November, 06 2018 16:05
Aptose to Present New CG-806 Data at the 2018 ASH Annual Meeting
SAN DIEGO and TORONTO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announc...
Source: GlobeNewswire
Date: November, 01 2018 09:26
Aptose Biosciences and CrystalGenomics announce issuance of European patent for CG-806
Aptose Biosciences (NASDAQ: APTO ) announces that the European Patent Office has issued European Patent No. EP2940014B1 for CG-806, a highly potent oral small molecule being developed for acute myeloid leukemia (AML), B cell and other hematologic malignancies. More news on: Aptose B...
Source: SeekingAlpha
Date: September, 27 2018 07:46
Aptose Biosciences and CrystalGenomics Announce Issuance of European Patent for CG-806
SAN DIEGO, TORONTO and SEOUL, South Korea, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that the European Patent Office (“EPO”) has issued European Patent No. EP2940...
Source: GlobeNewswire
Date: September, 27 2018 07:05
Aptose Biosciences (APTO) Presents At Rodman & Renshaw.C. Wainwright 20th Annual Global Investment Conference - Slideshow
The following slide deck was published by Aptose Biosciences Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: September, 05 2018 15:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-072.052.122.13982.02122,473
2018-12-062.182.062.181.84373,723
2018-12-052.272.182.302.13212,378
2018-12-042.272.172.302.17172,934
2018-12-032.312.252.382.18147,677

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0732,98361,72753.4337Short
2018-12-0636,320112,87232.1780Cover
2018-12-045,20032,91715.7973Cover
2018-12-0311,33950,80422.3191Cover
2018-11-302,70027,4919.8214Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on APTO.


About Aptose Biosciences. Inc. (NASDAQ: APTO)

Logo for Aptose Biosciences. Inc. (NASDAQ: APTO)

Lorus is a clinical stage cancer drug development company with a strong commitment to discovering and developing innovative molecular targeted therapies addressing major unmet medical needs.

 

Contact Information

 

 

Current Management

  • William G. Rice / President
  • Greg Chow / CFO
  • Saeid Babaei / VP, Bus. Affairs
  • Elizabeth Williams / IR

Current Share Structure

  • Market Cap: $92,131,878 - 05/14/2018
  • Issue and Outstanding: 27,502,053 - 12/31/2017

 


Recent Filings from (NASDAQ: APTO)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 17 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 10 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 10 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 09 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 07 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 25 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 17 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 16 2018

 

 


Daily Technical Chart for (NASDAQ: APTO)

Daily Technical Chart for (NASDAQ: APTO)


Stay tuned for daily updates and more on (NASDAQ: APTO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: APTO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in APTO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of APTO and does not buy, sell, or trade any shares of APTO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/